{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:45:08Z","timestamp":1791870308623,"version":"4.3.4"},"reference-count":110,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Endocrino Diabet &amp;amp; Metabol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inter\u2010individual variability in the therapeutic response to antidiabetic drugs is still a big problem in the management of type 2 diabetes mellitus (T2DM). Genetic polymorphisms of drug transporters, metabolizing enzymes and molecular targets have become significant factors in drug efficacy, pharmacokinetics and adverse effects. This review aims to provide a summary of the current evidence on the pharmacogenomics of metformin and sodium\u2010glucose cotransporter\u20102 (SGLT2) inhibitors and their implications for precision medicine in T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Published human studies examining genetic polymorphisms related to the various effects of metformin and SGLT2 inhibitors in patients with T2DM were systematically searched in PubMed, Scopus and EBSCO and analysed using an integrative review. Qualitative synthesis was used to compare the pharmacogenetic profiles of the two drug classes and to look for potential biomarkers for precision therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Metformin has the most comprehensive pharmacogenetic evidence, including variants in SLC22A1 (OCT1), SLC22A2 (OCT2), SLC22A3 (OCT3), SLC47A1 (MATE1), SLC47A2 (MATE2), ATM and other genes that affect drug disposition, glycemic response and adverse effects. However, pharmacogenetic research on SGLT2 inhibitors is still scarce. Modest variations in drug exposure, glucose homeostasis and cardiorenal or hepatic outcomes have been reported for variants of UGT1A9, UGT2B4, SLC5A2, PNPLA3, and some glucose transporters, but most of these effects have not been strong enough to recommend routine genotype\u2010based therapy. Metformin has more robust and consistent pharmacogenetic associations overall, while SGLT2 inhibitors have emerging but less definitive associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pharmacogenomics has great promise to enhance the selection of antidiabetic drugs, maximize therapeutic effect and minimize side effects. There is current evidence for the clinical relevance of several pharmacogenetic markers for metformin, but evidence for SGLT2 inhibitors is preliminary. Further, large, prospective, multiethnic studies and genotype\u2010based clinical trials are needed to confirm candidate biomarkers and to help incorporate pharmacogenomics into precision medicine for T2DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/edm2.70343","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:58:05Z","timestamp":1791867485000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gene\u2010Guided Therapy in Type 2 Diabetes Mellitus: An Integrative Review of the Pharmacogenetics of Metformin and Sodium\u2010Glucose Cotransporter\u20102 Inhibitors"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4891-4412","authenticated-orcid":false,"given":"Imran","family":"Hossain","sequence":"first","affiliation":[{"name":"Department of Pharmacy University of Asia Pacific  Dhaka Bangladesh"},{"name":"Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy University of Dhaka  Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9150-7379","authenticated-orcid":false,"given":"Mahnoor","family":"Haidar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Asia Pacific  Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6787-4421","authenticated-orcid":false,"given":"Mahfuj Ahmed","family":"Ratul","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Asia Pacific  Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0559-6460","authenticated-orcid":false,"given":"Jannatul Ferdous","family":"Sumona","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Asia Pacific  Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0674-262X","authenticated-orcid":false,"given":"Sraboni","family":"Shabnaz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Asia Pacific  Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5708-1045","authenticated-orcid":false,"given":"Abul Fojal","family":"Nokib","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Asia Pacific  Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6087-0425","authenticated-orcid":false,"family":"Fatema\u2010Tuz\u2010Zohora","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Asia Pacific  Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"18","key":"e_1_2_15_2_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186842","article-title":"Pharmacogenetics of Type 2 Diabetes\u2010Progress and Prospects","volume":"21","author":"Nasykhova Y. A.","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"e_1_2_15_3_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ndt\/gfaf177","article-title":"IDF Diabetes Atlas 11th Edition 2025: Global Prevalence and Projections for 2050","volume":"41","author":"Duncan B. B.","year":"2026","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"1","key":"e_1_2_15_4_1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/apha.12644","article-title":"Metformin Is Not Just an Antihyperglycaemic Drug but Also Has Protective Effects on the Vascular Endothelium","volume":"219","author":"Triggle C. R.","year":"2017","journal-title":"Acta Physiologica"},{"issue":"22","key":"e_1_2_15_5_1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman B.","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"e_1_2_15_6_1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4239\/wjd.v7.i15.302","article-title":"Pharmacogenetic Studies Update in Type 2 Diabetes Mellitus","volume":"7","author":"Singh S.","year":"2016","journal-title":"World Journal of Diabetes"},{"key":"e_1_2_15_7_1","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2147\/PGPM.S329787","article-title":"Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice","volume":"14","author":"Venkatachalapathy P.","year":"2021","journal-title":"Pharmacogenomics and Personalized Medicine"},{"issue":"5","key":"e_1_2_15_8_1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2648.2005.03621.x","article-title":"The Integrative Review: Updated Methodology","volume":"52","author":"Whittemore R.","year":"2005","journal-title":"Journal of Advanced Nursing"},{"issue":"15","key":"e_1_2_15_9_1","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.109.914820","article-title":"Pharmacogenomics: The Genetics of Variable Drug Responses","volume":"123","author":"Roden D. M.","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"e_1_2_15_10_1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.gpb.2016.03.008","article-title":"Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine","volume":"14","author":"Ahmed S.","year":"2016","journal-title":"Genomics, Proteomics & Bioinformatics"},{"issue":"9","key":"e_1_2_15_11_1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/17512433.2022.2118714","article-title":"Effects of Single\u2010Nucleotide Polymorphism on the Pharmacokinetics and Pharmacodynamics of Metformin","volume":"15","author":"Li S.","year":"2022","journal-title":"Expert Review of Clinical Pharmacology"},{"issue":"2","key":"e_1_2_15_12_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1208\/s12248-013-9460-z","article-title":"Influences of Organic Cation Transporter Polymorphisms on the Population Pharmacokinetics of Metformin in Healthy Subjects","volume":"15","author":"Yoon H.","year":"2013","journal-title":"AAPS Journal"},{"issue":"10","key":"e_1_2_15_13_1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40262-013-0076-3","article-title":"The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose\u2010Lowering Drugs","volume":"52","author":"Van Leeuwen N.","year":"2013","journal-title":"Clinical Pharmacokinetics"},{"issue":"4","key":"e_1_2_15_14_1","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/cpt.2357","article-title":"Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race\u2010Conscious Medicine","volume":"110","author":"Davis B. H.","year":"2021","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"e_1_2_15_15_1","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/415149","article-title":"Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?","volume":"2015","author":"Pollastro C.","year":"2015","journal-title":"PPAR Research"},{"issue":"3","key":"e_1_2_15_16_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1900\/RDS.2015.12.363","article-title":"Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy","volume":"12","author":"Staiger H.","year":"2015","journal-title":"Review of Diabetic Studies"},{"issue":"1","key":"e_1_2_15_17_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","article-title":"Cellular and Molecular Mechanisms of Metformin Action","volume":"42","author":"LaMoia T. E.","year":"2021","journal-title":"Endocrine Reviews"},{"key":"e_1_2_15_18_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.coph.2020.10.018","article-title":"Metformin: Still the Sweet Spot for CV Protection in Diabetes?","volume":"54","author":"Rena G.","year":"2020","journal-title":"Current Opinion in Pharmacology"},{"issue":"4","key":"e_1_2_15_19_1","doi-asserted-by":"crossref","DOI":"10.3390\/ph17040478","article-title":"View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex\u2010Related Differences","volume":"17","author":"Froldi G.","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"2","key":"e_1_2_15_20_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.108900","article-title":"Insights Into the Action of the Pharmaceutical Metformin: Targeted Inhibition of the Gut Microbial Enzyme Agmatinase","volume":"27","author":"Tassoulas L. J.","year":"2024","journal-title":"iScience"},{"issue":"1","key":"e_1_2_15_21_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12902-024-01727-w","article-title":"Gastrointestinal Adverse Events of Metformin Treatment in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta\u2010Analysis With Meta\u2010Regression of Observational Studies","volume":"24","author":"Nabrdalik K.","year":"2024","journal-title":"BMC Endocrine Disorders"},{"key":"e_1_2_15_22_1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.biopha.2018.07.085","article-title":"A Preclinical Overview of Metformin for the Treatment of Type 2 Diabetes","volume":"106","author":"Zhou T.","year":"2018","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"2","key":"e_1_2_15_23_1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1208\/s12248-013-9465-7","article-title":"Organic Cation Transporters OCTs (SLC22) and MATEs (SLC47) in the Human Kidney","volume":"15","author":"Motohashi H.","year":"2013","journal-title":"AAPS Journal"},{"issue":"1","key":"e_1_2_15_24_1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12902-022-01033-3","article-title":"Role of Human Organic Cation Transporter\u20101 (OCT\u20101\/SLC22A1) in Modulating the Response to Metformin in Patients With Type 2 Diabetes","volume":"22","author":"Kawoosa F.","year":"2022","journal-title":"BMC Endocrine Disorders"},{"issue":"5","key":"e_1_2_15_25_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2217\/dmt.12.42","article-title":"Molecular Action and Pharmacogenetics of Metformin: Current Understanding of an Old Drug","volume":"2","author":"Rena G.","year":"2012","journal-title":"Diabetes Management"},{"issue":"8","key":"e_1_2_15_26_1","first-page":"9533","article-title":"Genetic Variants of OCT1 Influence Glycemic Response to Metformin in Han Chinese Patients With Type 2 Diabetes Mellitus in Shanghai","volume":"8","author":"Zhou Y.","year":"2015","journal-title":"International Journal of Clinical and Experimental Pathology"},{"issue":"6","key":"e_1_2_15_27_1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4103\/1735-5362.389949","article-title":"Association of SLC22A1, SLC47A1, and KCNJ11 Polymorphisms With Efficacy and Safety of Metformin and Sulfonylurea Combination Therapy in Egyptian Patients With Type 2 Diabetes","volume":"18","author":"Ahmed A.","year":"2023","journal-title":"Research in Pharmaceutical Sciences"},{"issue":"1","key":"e_1_2_15_28_1","doi-asserted-by":"crossref","DOI":"10.3390\/jpm9010017","article-title":"Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels","volume":"9","author":"Al\u2010Eitan L. N.","year":"2019","journal-title":"Journal of Personalized Medicine"},{"issue":"4","key":"e_1_2_15_29_1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10238-014-0322-5","article-title":"Influence of SLC22A1 rs622342 Genetic Polymorphism on Metformin Response in South Indian Type 2 Diabetes Mellitus Patients","volume":"15","author":"Umamaheswaran G.","year":"2015","journal-title":"Clinical and Experimental Medicine"},{"issue":"12","key":"e_1_2_15_30_1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/FPC.0b013e32834c0010","article-title":"The Pharmacogenetics of Metformin and Its Impact on Plasma Metformin Steady\u2010State Levels and Glycosylated Hemoglobin A1c","volume":"21","author":"Christensen M. M.","year":"2011","journal-title":"Pharmacogenetics and Genomics"},{"issue":"2","key":"e_1_2_15_31_1","doi-asserted-by":"crossref","DOI":"10.3892\/br.2024.1806","article-title":"Impact of SLC22A1 Variants rs622342 and rs72552763 on HbA1c and Metformin Plasmatic Concentration Levels in Patients With Type 2 Diabetes Mellitus","volume":"21","author":"Ortega\u2010Ayala A.","year":"2024","journal-title":"Biomedical Reports"},{"issue":"4","key":"e_1_2_15_32_1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/tpj.2009.15","article-title":"Genetic Variation in the Organic Cation Transporter 1 Is Associated With Metformin Response in Patients With Diabetes Mellitus","volume":"9","author":"Becker M. L.","year":"2009","journal-title":"Pharmacogenomics Journal"},{"issue":"3","key":"e_1_2_15_33_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/clpt.2009.92","article-title":"The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin","volume":"86","author":"Tzvetkov M. V.","year":"2009","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"e_1_2_15_34_1","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4350712","article-title":"The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients","volume":"2016","author":"Xiao D.","year":"2016","journal-title":"International Journal of Endocrinology"},{"issue":"10","key":"e_1_2_15_35_1","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.2337\/db10-0543","article-title":"Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program","volume":"59","author":"Jablonski K. A.","year":"2010","journal-title":"Diabetes"},{"issue":"11","key":"e_1_2_15_36_1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2217\/pgs-2018-0041","article-title":"Implication of Critical Pharmacokinetic Gene Variants on Therapeutic Response to Metformin in Type 2 Diabetes","volume":"19","author":"Phani N. M.","year":"2018","journal-title":"Pharmacogenomics"},{"issue":"5","key":"e_1_2_15_37_1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/clpt.2008.61","article-title":"Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin","volume":"84","author":"Song I. S.","year":"2008","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"5","key":"e_1_2_15_38_1","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.486","article-title":"The Influence of OCT3 and MATE2 Genetic Polymorphisms in Poor Response to Metformin in Type 2 Diabetes Mellitus","volume":"7","author":"Naem A. A.","year":"2024","journal-title":"Endocrinology, Diabetes & Metabolism"},{"key":"e_1_2_15_39_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2022.146382","article-title":"The Influence of SLC22A3 rs543159 and rs1317652 Genetic Variants on Metformin Therapeutic Efficacy in Newly Diagnosed Patients With Type 2 Diabetes Mellitus: 25\u2009Weeks Follow\u2010Up Study","volume":"823","author":"Taheri R.","year":"2022","journal-title":"Gene"},{"issue":"3","key":"e_1_2_15_40_1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2337\/db08-1028","article-title":"Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose\u2010Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study","volume":"58","author":"Becker M. L.","year":"2009","journal-title":"Diabetes"},{"issue":"4","key":"e_1_2_15_41_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/dmpt-2018-0030","article-title":"Lack of Effect of the SLC47A1 and SLC47A2 Gene Polymorphisms on the Glycemic Response to Metformin in Type 2 Diabetes Mellitus Patients","volume":"33","author":"Raj G. M.","year":"2018","journal-title":"Drug Metabolism and Personalized Therapy"},{"issue":"12","key":"e_1_2_15_42_1","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/ijcp.12534","article-title":"RS11212617 Is Associated With Metformin Treatment Response in Type 2 Diabetes in Shanghai Local Chinese Population","volume":"68","author":"Zhou Y.","year":"2014","journal-title":"International Journal of Clinical Practice"},{"issue":"7","key":"e_1_2_15_43_1","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00125-012-2537-x","article-title":"A Gene Variant Near ATM Is Significantly Associated With Metformin Treatment Response in Type 2 Diabetes: A Replication and Meta\u2010Analysis of Five Cohorts","volume":"55","author":"Van Leeuwen N.","year":"2012","journal-title":"Diabetologia"},{"issue":"9","key":"e_1_2_15_44_1","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.xphs.2017.04.078","article-title":"Transporters Involved in Metformin Pharmacokinetics and Treatment Response","volume":"106","author":"Liang X.","year":"2017","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"7","key":"e_1_2_15_45_1","doi-asserted-by":"crossref","DOI":"10.3390\/ph15070810","article-title":"Metabolic Action of Metformin","volume":"15","author":"Szymczak\u2010Pajor I.","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"5","key":"e_1_2_15_46_1","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of Genetic Variation in the Organic Cation Transporter 1 (OCT1) on Metformin Action","volume":"117","author":"Shu Y.","year":"2007","journal-title":"Journal of Clinical Investigation"},{"issue":"6","key":"e_1_2_15_47_1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/cpt.567","article-title":"Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A MetGen Meta\u2010Analysis","volume":"101","author":"Dujic T.","year":"2017","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"8","key":"e_1_2_15_48_1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP\u2010Activated Protein Kinase in Mechanism of Metformin Action","volume":"108","author":"Zhou G.","year":"2001","journal-title":"Journal of Clinical Investigation"},{"issue":"1","key":"e_1_2_15_49_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s43042-023-00388-z","article-title":"Genetic Polymorphism of Organic Cation Transporter 2 (OCT2) and Its Effects on the Pharmacokinetics and Pharmacodynamics of Metformin: A Narrative Review","volume":"24","author":"Borra S. S.","year":"2023","journal-title":"Egyptian Journal of Medical Human Genetics"},{"issue":"11","key":"e_1_2_15_50_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FPC.0b013e32833fe789","article-title":"Role of Organic Cation Transporter 3 (SLC22A3) and Its Missense Variants in the Pharmacologic Action of Metformin","volume":"20","author":"Chen L.","year":"2010","journal-title":"Pharmacogenetics and Genomics"},{"issue":"11","key":"e_1_2_15_51_1","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","article-title":"Metformin Pathways: Pharmacokinetics and Pharmacodynamics","volume":"22","author":"Gong L.","year":"2012","journal-title":"Pharmacogenetics and Genomics"},{"issue":"2","key":"e_1_2_15_52_1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/clpt.2012.210","article-title":"The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin","volume":"93","author":"Stocker S. L.","year":"2013","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"7","key":"e_1_2_15_53_1","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1476-5381.2011.01394.x","article-title":"Importance of the Multidrug and Toxin Extrusion MATE\/SLC47A Family to Pharmacokinetics, Pharmacodynamics\/Toxicodynamics and Pharmacogenomics","volume":"164","author":"Yonezawa A.","year":"2011","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"e_1_2_15_54_1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/jpm13030489","article-title":"Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers","volume":"13","author":"Saiz\u2010Rodr\u00edguez M.","year":"2023","journal-title":"Journal of Personalized Medicine"},{"issue":"9","key":"e_1_2_15_55_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093240","article-title":"The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective","volume":"21","author":"Agius L.","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"e_1_2_15_56_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/ng.735","article-title":"Common Variants Near ATM Are Associated With Glycemic Response to Metformin in Type 2 Diabetes","volume":"43","author":"Harries L. W.","year":"2011","journal-title":"Nature Genetics"},{"issue":"5","key":"e_1_2_15_57_1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2174\/1573399815666191105151828","article-title":"Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes","volume":"16","author":"Asrih M.","year":"2020","journal-title":"Current Diabetes Reviews"},{"issue":"1","key":"e_1_2_15_58_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: A Review","volume":"21","author":"Ehrenkranz J. R.","year":"2005","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"issue":"6","key":"e_1_2_15_59_1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1172\/JCI100559","article-title":"The Action of Phlorizin on the Excretion of Glucose, Xylose, Sucrose, Creatinine and Urea by Man","volume":"12","author":"Chasis H.","year":"1933","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"e_1_2_15_60_1","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of Hyperglycemia With Phlorizin Normalizes Tissue Sensitivity to Insulin in Diabetic Rats","volume":"79","author":"Rossetti L.","year":"1987","journal-title":"Journal of Clinical Investigation"},{"issue":"20","key":"e_1_2_15_61_1","doi-asserted-by":"crossref","first-page":"14112","DOI":"10.1074\/jbc.274.20.14112","article-title":"Chronic Hyperglycemia Triggers Loss of Pancreatic \u03b2 Cell Differentiation in an Animal Model of Diabetes","volume":"274","author":"Jonas J. C.","year":"1999","journal-title":"Journal of Biological Chemistry"},{"issue":"4","key":"e_1_2_15_62_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.ki.5002701","article-title":"High Prevalence of Chronic Kidney Disease in Thailand","volume":"73","author":"Perkovic V.","year":"2008","journal-title":"Kidney International"},{"issue":"1","key":"e_1_2_15_63_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","article-title":"Active Sugar Transport in Health and Disease","volume":"261","author":"Wright E. M.","year":"2007","journal-title":"Journal of Internal Medicine"},{"key":"e_1_2_15_64_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium\u2010Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review","volume":"8","author":"Fonseca\u2010Correa J. I.","year":"2021","journal-title":"Frontiers in Medicine"},{"issue":"13","key":"e_1_2_15_65_1","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 Protein Inhibition Decreases Renal Lipid Accumulation, Inflammation, and the Development of Nephropathy in Diabetic Mice","volume":"292","author":"Wang X. X.","year":"2017","journal-title":"Journal of Biological Chemistry"},{"issue":"4","key":"e_1_2_15_66_1","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/jcm12041356","article-title":"The Sodium\u2010Glucose Co\u2010Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia\u2010Induced Monocyte and Endothelial Dysfunction Primarily Through Glucose Transport\u2010Independent but Redox\u2010Dependent Mechanisms","volume":"12","author":"Semo D.","year":"2023","journal-title":"Journal of Clinical Medicine"},{"issue":"6","key":"e_1_2_15_67_1","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00125-021-05402-w","article-title":"Pharmacogenetics of Novel Glucose\u2010Lowering Drugs","volume":"64","author":"Rathmann W.","year":"2021","journal-title":"Diabetologia"},{"issue":"18","key":"e_1_2_15_68_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189800","article-title":"Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations","volume":"22","author":"Klen J.","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"9","key":"e_1_2_15_69_1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/jcph.506","article-title":"In Vitro Metabolism of Canagliflozin in Human Liver, Kidney, Intestine Microsomes, and Recombinant Uridine Diphosphate Glucuronosyltransferases (UGT) and the Effect of Genetic Variability of UGT Enzymes on the Pharmacokinetics of Canagliflozin in Humans","volume":"55","author":"Francke S.","year":"2015","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"e_1_2_15_70_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40262-015-0307-x","article-title":"Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus","volume":"55","author":"Hoeben E.","year":"2016","journal-title":"Clinical Pharmacokinetics"},{"issue":"4","key":"e_1_2_15_71_1","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/bcp.15117","article-title":"Common UGT1A9 Polymorphisms Do Not Have a Clinically Meaningful Impact on the Apparent Oral Clearance of Dapagliflozin in Type 2 Diabetes Mellitus","volume":"88","author":"Naagaard M. D.","year":"2022","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"9","key":"e_1_2_15_72_1","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/jcph.1866","article-title":"Meta\u2010Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure","volume":"61","author":"Marshall J. C.","year":"2021","journal-title":"Journal of Clinical Pharmacology"},{"key":"e_1_2_15_73_1","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2147\/DMSO.S464671","article-title":"The Impact of Genetic Polymorphisms on the Anti\u2010Hyperglycemic Effect of Dapagliflozin","volume":"17","author":"Wang Z.","year":"2024","journal-title":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"},{"key":"e_1_2_15_74_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1539870","article-title":"Genetic Polymorphisms in SLC5A2 Are Associated With Clinical Outcomes and Dapagliflozin Response in Heart Failure Patients","volume":"16","author":"Abou Warda A. E.","year":"2025","journal-title":"Frontiers in Pharmacology"},{"issue":"9","key":"e_1_2_15_75_1","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of Dapagliflozin and n\u20103 Carboxylic Acids on Non\u2010Alcoholic Fatty Liver Disease in People With Type 2 Diabetes: A Double\u2010Blind Randomised Placebo\u2010Controlled Study","volume":"61","author":"Eriksson J. W.","year":"2018","journal-title":"Diabetologia"},{"issue":"6","key":"e_1_2_15_76_1","first-page":"844","article-title":"An Intron Variant of SLC2A9 Increases the Risk for Type 2 Diabetes Mellitus Complicated With Hyperuricemia in Chinese Male Population","volume":"47","author":"Yi X. L.","year":"2018","journal-title":"Iranian Journal of Public Health"},{"issue":"8","key":"e_1_2_15_77_1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2217\/pgs.11.69","article-title":"Role of Genetic Variation in the Human Sodium\u2010Glucose Cotransporter 2 Gene (SGLT2) in Glucose Homeostasis","volume":"12","author":"Enigk U.","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"5","key":"e_1_2_15_78_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177148","article-title":"Common Variation in the Sodium\/Glucose Cotransporter 2 Gene SLC5A2 Does Neither Affect Fasting nor Glucose\u2010Suppressed Plasma Glucagon Concentrations","volume":"12","author":"Ordelheide A. M.","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"e_1_2_15_79_1","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190299","article-title":"Are SGLT2 Polymorphisms Linked to Diabetes Mellitus and Cardiovascular Disease? Prospective Study and Meta\u2010Analysis","volume":"39","author":"Drexel H.","year":"2019","journal-title":"Bioscience Reports"},{"issue":"3","key":"e_1_2_15_80_1","first-page":"276","article-title":"Genetic Variability in Sodium\u2010Glucose Cotransporter 2 Influences Glycemic Control and Risk for Diabetic Retinopathy in Type 2 Diabetes Patients","volume":"39","author":"Klen J.","year":"2020","journal-title":"Journal of Medical Biochemistry"},{"issue":"4","key":"e_1_2_15_81_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/FPC.0000000000000268","article-title":"Influence of Common Polymorphisms in the SLC5A2 Gene on Metabolic Traits in Subjects at Increased Risk of Diabetes and on Response to Empagliflozin Treatment in Patients With Diabetes","volume":"27","author":"Zimdahl H.","year":"2017","journal-title":"Pharmacogenetics and Genomics"},{"issue":"12","key":"e_1_2_15_82_1","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17121604","article-title":"Pharmacokinetic Landscape and Interaction Potential of SGLT2 Inhibitors: Bridging In\u00a0Vitro Findings and Clinical Implications","volume":"17","author":"Koo N.","year":"2025","journal-title":"Pharmaceutics"},{"issue":"2","key":"e_1_2_15_83_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium Glucose Co\u2010Transporter\u20102 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology","volume":"5","author":"Kalra S.","year":"2014","journal-title":"Diabetes Therapy"},{"issue":"10","key":"e_1_2_15_84_1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40262-015-0285-z","article-title":"Clinical Pharmacokinetic, Pharmacodynamic, and Drug\u2013Drug Interaction Profile of Canagliflozin, a Sodium\u2010Glucose Co\u2010Transporter 2 Inhibitor","volume":"54","author":"Devineni D.","year":"2015","journal-title":"Clinical Pharmacokinetics"},{"issue":"5","key":"e_1_2_15_85_1","first-page":"1015","article-title":"Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis","volume":"10","author":"Gabriel\u2010Medina P.","year":"2022","journal-title":"Biomedicine"},{"issue":"4","key":"e_1_2_15_86_1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.34067\/KID.0000000790","article-title":"Sodium\u2010Glucose Transporter 2: Untangling the Mingled Yarn of Genetic and Pharmacologic Inhibition","volume":"6","author":"Gulati A.","year":"2025","journal-title":"Kidney360"},{"key":"e_1_2_15_87_1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.genrep.2016.11.006","article-title":"Glucose Transporter 1 (GLUT1) Gene Frequency Distribution of XbaI G>T and HaeIII T>C Polymorphisms Among Different West Indian Patients With Type 2 Diabetes Mellitus","volume":"6","author":"Lal S.","year":"2017","journal-title":"Gene Reports"},{"issue":"9","key":"e_1_2_15_88_1","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00125-012-2595-0","article-title":"SLC2A2 Mutations Can Cause Neonatal Diabetes, Suggesting GLUT2 May Have a Role in Human Insulin Secretion","volume":"55","author":"Sansbury F. H.","year":"2012","journal-title":"Diabetologia"},{"issue":"9","key":"e_1_2_15_89_1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00424-020-02383-4","article-title":"Glucose Transporters in Pancreatic Islets","volume":"472","author":"Berger C.","year":"2020","journal-title":"Pfl\u00fcgers Archiv\u2010European Journal of Physiology"},{"issue":"2","key":"e_1_2_15_90_1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week","volume":"83","author":"Packer M.","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"key":"e_1_2_15_91_1","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221083509","article-title":"Effect of Sodium\u2010Glucose Cotransporter\u20102 (SGLT2) Inhibitors on Serum Urate Levels in Patients With and Without Diabetes: A Systematic Review and Meta\u2010Regression of 43 Randomized Controlled Trials","volume":"13","author":"Yip A. S.","year":"2022","journal-title":"Therapeutic Advances in Chronic Disease"},{"issue":"6","key":"e_1_2_15_92_1","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.62347\/YNWL3428","article-title":"Long\u2010Term Effects of Metformin Versus Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Patients With Type 2 Diabetes","volume":"17","author":"Hao X.","year":"2025","journal-title":"American Journal of Translational Research"},{"issue":"8","key":"e_1_2_15_93_1","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032397","article-title":"Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study","volume":"13","author":"Chang H. C.","year":"2024","journal-title":"Journal of the American Heart Association"},{"issue":"4","key":"e_1_2_15_94_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2217\/pgs.14.21","article-title":"An Update on the Pharmacogenomics of Metformin: Progress, Problems and Potential","volume":"15","author":"Todd J. N.","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"6","key":"e_1_2_15_95_1","first-page":"659","article-title":"Pharmacogenetics of New Classes of Antidiabetic Drugs","volume":"21","author":"Kadri\u0107 S. I.","year":"2021","journal-title":"Bosnian Journal of Basic Medical Sciences"},{"key":"e_1_2_15_96_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.800490","article-title":"Effects of Sodium\u2010Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism","volume":"13","author":"Tang J.","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"6","key":"e_1_2_15_97_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101285","article-title":"The Diuretic Effects of SGLT2 Inhibitors: A Comprehensive Review of Their Specificities and Their Role in Renal Protection","volume":"47","author":"Delanaye P.","year":"2021","journal-title":"Diabetes & Metabolism"},{"issue":"1","key":"e_1_2_15_98_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining Glucagon\u2010Like Peptide\u20101 Receptor Agonists (GLP\u20101RAs) and Sodium\u2010Glucose Cotransporter\u20102 Inhibitors (SGLT2is) in Patients With Type 2 Diabetes Mellitus (T2DM)","volume":"22","author":"Gourdy P.","year":"2023","journal-title":"Cardiovascular Diabetology"},{"issue":"11","key":"e_1_2_15_99_1","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3390\/diagnostics14111194","article-title":"Sodium\u2010Glucose Cotransporter 2 Inhibitor Combined With Conventional Diuretics Ameliorate Body Fluid Retention Without Excessive Plasma Volume Reduction","volume":"14","author":"Asakura\u2010Kinoshita M.","year":"2024","journal-title":"Diagnostics"},{"issue":"4","key":"e_1_2_15_100_1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.15171\/apb.2017.062","article-title":"Drug Interactions of Metformin Involving Drug Transporter Proteins","volume":"7","author":"Maideen N. M.","year":"2017","journal-title":"Advanced Pharmaceutical Bulletin"},{"issue":"4","key":"e_1_2_15_101_1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40262-013-0128-8","article-title":"Drug\u2013Drug Interactions With Sodium\u2010Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose\u2010Lowering Agents for the Management of Type 2 Diabetes Mellitus","volume":"53","author":"Scheen A. J.","year":"2014","journal-title":"Clinical Pharmacokinetics"},{"issue":"1","key":"e_1_2_15_102_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/cpt.2153","article-title":"Genetic Variation in Sodium\u2010Glucose Cotransporter 2 and Heart Failure","volume":"110","author":"Katzmann J. L.","year":"2021","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"1","key":"e_1_2_15_103_1","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad470","article-title":"Applying Polygenic Risk Score Methods to Pharmacogenomics GWAS: Challenges and Opportunities","volume":"25","author":"Zhai S.","year":"2024","journal-title":"Briefings in Bioinformatics"},{"key":"e_1_2_15_104_1","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1000667","article-title":"Polygenic Risk Scores: An Overview From Bench to Bedside for Personalised Medicine","volume":"13","author":"Cross B.","year":"2022","journal-title":"Frontiers in Genetics"},{"issue":"2","key":"e_1_2_15_105_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13300-024-01676-6","article-title":"Integrating Polygenic Risk Scores (PRS) for Personalized Diabetes Care: Advancing Clinical Practice With Tailored Pharmacological Approaches","volume":"16","author":"Singh O.","year":"2025","journal-title":"Diabetes Therapy"},{"issue":"9","key":"e_1_2_15_106_1","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1007\/s00125-017-4335-y","article-title":"The Pharmacogenetics of Metformin","volume":"60","author":"Florez J. C.","year":"2017","journal-title":"Diabetologia"},{"key":"e_1_2_15_107_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1506767","article-title":"Advancements in Precision Medicine: Multi\u2010Omics Approach for Tailored Metformin Treatment in Type 2 Diabetes","volume":"15","author":"Anwardeen N. R.","year":"2024","journal-title":"Frontiers in Pharmacology"},{"issue":"2","key":"e_1_2_15_108_1","first-page":"447","article-title":"Harnessing Pharmacomultiomics for Precision Medicine in Diabetes: A Comprehensive Review","volume":"13","author":"Dhieb D.","year":"2025","journal-title":"Biomedicine"},{"issue":"1","key":"e_1_2_15_109_1","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2558071","article-title":"Systemic and Gut Microbiome Changes With Metformin and Liraglutide in Youth\u2010Onset Type 2 Diabetes: The MIGHTY Study","volume":"17","author":"Glaros S. B.","year":"2025","journal-title":"Gut Microbes"},{"issue":"7","key":"e_1_2_15_110_1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41574-022-00671-w","article-title":"Epigenetics of Type 2 Diabetes Mellitus and Weight Change\u2014A Tool for Precision Medicine?","volume":"18","author":"Ling C.","year":"2022","journal-title":"Nature Reviews Endocrinology"},{"issue":"7","key":"e_1_2_15_111_1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/jpm15070294","article-title":"Clinician Experiences at the Frontier of Pharmacogenomics and Future Directions","volume":"15","author":"Thottunkal S.","year":"2025","journal-title":"Journal of Personalized Medicine"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70343","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/edm2.70343","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:58:19Z","timestamp":1791867499000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/edm2.70343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":110,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1002\/edm2.70343"],"URL":"https:\/\/doi.org\/10.1002\/edm2.70343","archive":["Portico"],"relation":{},"ISSN":["2398-9238","2398-9238"],"issn-type":[{"value":"2398-9238","type":"print"},{"value":"2398-9238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"2026-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70343"}}